Beta Bionics (BBNX) Competitors $18.84 +0.13 (+0.69%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BBNX vs. LQDA, PRCT, LMAT, AORT, EYE, ENOV, CNMD, NVCR, SSII, and BLFSShould you be buying Beta Bionics stock or one of its competitors? The main competitors of Beta Bionics include Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry. Beta Bionics vs. Its Competitors Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Enovis CONMED NovoCure SS Innovations International BioLife Solutions Beta Bionics (NASDAQ:BBNX) and Liquidia Technologies (NASDAQ:LQDA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Does the media favor BBNX or LQDA? In the previous week, Liquidia Technologies had 5 more articles in the media than Beta Bionics. MarketBeat recorded 11 mentions for Liquidia Technologies and 6 mentions for Beta Bionics. Liquidia Technologies' average media sentiment score of 1.32 beat Beta Bionics' score of 1.32 indicating that Liquidia Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia Technologies 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BBNX or LQDA? Beta Bionics currently has a consensus target price of $22.56, indicating a potential upside of 19.72%. Liquidia Technologies has a consensus target price of $32.11, indicating a potential upside of 16.01%. Given Beta Bionics' higher probable upside, equities research analysts plainly believe Beta Bionics is more favorable than Liquidia Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beta Bionics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Liquidia Technologies 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in BBNX or LQDA? 64.5% of Liquidia Technologies shares are held by institutional investors. 30.1% of Liquidia Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is BBNX or LQDA more profitable? Beta Bionics has a net margin of 0.00% compared to Liquidia Technologies' net margin of -732.17%. Beta Bionics' return on equity of 0.00% beat Liquidia Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Beta BionicsN/A N/A N/A Liquidia Technologies -732.17%-232.96%-60.81% Which has higher valuation and earnings, BBNX or LQDA? Beta Bionics has higher revenue and earnings than Liquidia Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeta Bionics$78.02M10.50-$54.76MN/AN/ALiquidia Technologies$14M170.21-$130.39M-$1.70-16.28 SummaryLiquidia Technologies beats Beta Bionics on 7 of the 13 factors compared between the two stocks. Get Beta Bionics News Delivered to You Automatically Sign up to receive the latest news and ratings for BBNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBNX vs. The Competition Export to ExcelMetricBeta BionicsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$818.98M$6.89B$5.69B$9.74BDividend YieldN/A1.20%6.66%4.48%P/E RatioN/A26.1883.1926.59Price / Sales10.5071.66515.16159.07Price / CashN/A22.4425.6628.92Price / Book-3.294.9611.766.08Net Income-$54.76M$176.38M$3.27B$265.93M7 Day Performance7.97%1.34%1.13%0.36%1 Month Performance14.88%4.21%8.30%5.58%1 Year PerformanceN/A7.54%62.26%19.67% Beta Bionics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBNXBeta BionicsN/A$18.84+0.7%$22.56+19.7%N/A$818.98M$78.02M0.00294News CoverageLQDALiquidia Technologies3.5433 of 5 stars$27.30-0.2%$32.11+17.6%+191.1%$2.35B$14M-16.0650PRCTPROCEPT BioRobotics3.6484 of 5 stars$39.35-0.1%$74.88+90.3%-49.2%$2.19B$224.50M-25.39430Positive NewsLMATLeMaitre Vascular2.5926 of 5 stars$96.45-0.3%$97.60+1.2%+5.6%$2.19B$219.86M46.82490Positive NewsAORTArtivion3.1733 of 5 stars$43.12+0.2%$39.80-7.7%+61.6%$2.03B$388.54M-102.651,600EYENational Vision2.839 of 5 stars$24.04-0.7%$24.73+2.9%+117.2%$1.92B$1.89B-133.5613,411Positive NewsInsider TradeENOVEnovis4.4633 of 5 stars$29.44-1.9%$51.00+73.3%-33.7%$1.71B$2.11B-2.077,367Positive NewsCNMDCONMED4.2953 of 5 stars$53.03-0.8%$59.80+12.8%-25.8%$1.65B$1.31B15.023,900Positive NewsNVCRNovoCure3.9312 of 5 stars$11.91+1.1%$28.79+141.7%-36.6%$1.32B$605.22M-7.631,488SSIISS Innovations InternationalN/A$7.54+17.1%N/AN/A$1.25B$20.65M0.004High Trading VolumeBLFSBioLife Solutions2.2386 of 5 stars$25.08+0.5%$31.29+24.7%-3.2%$1.20B$82.25M-208.98440 Related Companies and Tools Related Companies Liquidia Technologies Competitors PROCEPT BioRobotics Competitors LeMaitre Vascular Competitors Artivion Competitors National Vision Competitors Enovis Competitors CONMED Competitors NovoCure Competitors SS Innovations International Competitors BioLife Solutions Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBNX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
